SKYTROFA® Auto-Injector Award
In collaboration with their customer, Ascendis Pharma, Phillips-Medisize was recently recognized with a third prestigious industry award for the SKYTROFA® Auto-Injector. The award recognizes the drug delivery device’s exceptional design and positive impact. The first-of-its-kind product that enables convenient and efficient preparation and delivery of SKYTROFA—a vital growth hormone treatment for children.
The design award was presented during the Red Dot Design Awards on June 19 in Essen, Germany. “The product features excellent ease of use and optics, as well as very convenient and safe process control with reduced pharmaceutical waste,” the Red Dot jury stated.
Impact on Pediatric Care
Traditionally, children requiring growth hormone treatments had endured daily injections that often led to nonadherence to therapy, due to pain and/or bruising with injection as well as fear of needles. The introduction of the SKYTROFA has reduced the frequency of injections to just once a week, while using a discreet needle.
The breakthrough technology behind the Auto-injector represents a significant advance in usability that enhances the quality of life and safety for the young patient and their families.
How It Works
SKYTROFA is a lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and water in the other.
The cartridge is designed for subcutaneous injection once a week with the Auto-Injector. The Auto-Injector provides a fully automated reconstitution of the lyophilized drug product, followed by a manual mixing step controlled by the device. The device automatically delivers the drug product after inserting the injection needle into the skin.
Built-in electronics and software assist the user during the entire preparation and injection sequence and confirm that the full dosage is delivered.
The device is reusable and rechargeable. It eliminates the waste of disposable injector pens and batteries with a full charge lasting four weeks, with one weekly injection. The life of the Auto-Injector is approximately four years or 210 injections.
About the Red Dot Awards
The Red Dot Design Award is an internationally recognized symbol of excellence in design innovation. Each year, the jury evaluates thousands of entries across various industries to identify products that embody outstanding design concepts, aesthetic appeal, and functional excellence.
The SKYTROFA Auto-injector joins the ranks of visionary designs from healthcare and consumer product companies that transform the lives of individuals worldwide.
In May 2022, the SKYTROFA Auto-Injector received the Pharmapack Health Product Award for Patient-Centric Design. The jury described the device as a great all-in-one product with easy-to-follow steps for patients.
In October 2022, the SKYTROFA Auto-Injector received the Parenteral Drug Association (PDA) Innovation Award. The PDA Drug Delivery Awards were introduced in 2019 to recognize technical innovations that advance the bio/pharmaceutical manufacturing field.